Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Efavirenz/emtricitabine/tenofovir disoproxil fumarate to Bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV-positive patients
2018-003880-79Phase 4Completed
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoint: Virologic suppression at week 24. Started Jun 2021; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2018-003880-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003880-79.